


ERG MULTIFOCAL PRINCIPES ET INDICATIONS



Pr MINA LAGHMARI


LIMITES DE L'ERG GLOBAL

- **Réponse de masse des 2 systèmes (cônes et bâtonnets)**
- L'ERG global peut rester normal alors que 20% à 30% de la surface de la rétine est affectée!
- DMLA avancées, autres maculopathies...
- Correlation clinique nécessaire



INTÉRÊT DE L'ERG MULTIFOCAL


- Repérer les **zones rétiniennes du pôle post** qui présentent des **réponses d'amplitudes diminuées** par rapport aux **zones voisines**.
- Localiser des dysfonctionnements **rétiniens centraux non systématisés**.



CASE STUDY

CAS N°1


- L H, 38 ans, ATCD=0
- BAV récente de l'OD,
- MAVC: **OD: 4/10**
OG: 10/10
- LAF + FO+ AF: RAS
- OCT macula: RAS?



EXAMEN D'ELECTROPHYSIOLOGIE VISUELLE


PEV flashes 1mn 6s Val= 60 Rej= 0

OD stimulé




PEV flashes 3mn 20s Val= 60 Rej= 0

OG stimulé




PEV flashes 2mn 36s Val= 60 Rej= 0

Bi stimulé




PEV damier 60' 0mn 49s Val= 60 Rej= 0

OD stimulé




PEV damier 30' 2mn 2s Val= 55 Rej= 0

OD stimulé




PEV damier 15' 2mn 54s Val= 55 Rej= 0

OD stimulé




PEV damier 60' 1mn 7s Val= 60 Rej= 0

OG stimulé




PEV damier 30' 2mn 6s Val= 60 Rej= 0

OG stimulé




PEV damier 15' 3mn 1s Val= 60 Rej= 0

OG stimulé



EXAMEN D'ELECTROPHYSIOLOGIE MULTIFOCALE

MERG61B CARTE DES REPONSES LOCALES




MERG61B ANALYSE PAR ZONES (anneaux)




EXAMEN D'ELECTROPHYSIOLOGIE MULTIFOCALE


MERG61B CARTE DES REPONSES LOCALES




MERG61B ANALYSE PAR ZONES (anneaux)




MERG61B CARTE AMPLITUDES ONDE P1




MERG61B CARTE AMPLITUDES ONDE P1




MERG61B CARTE AMPLITUDES ONDE P1




MERG61B CARTE AMPLITUDES ONDE P1






OD



OG

CAS N°1

- L H, 38 ans, ATCD=0
- BAV récente de l'OD,
- MAVC: **OD: 4/10**, OG: 10/10
- LAF + FO+ AF: RAS





MERG61B
OD stimulé

CARTE DES REPONSES LOCALES

MERG10 D
OG stimulé


CARTE DES REPONSES LOCALES

Diagnostic:
dystrophie maculaire occulte ?



CAS N°2


- D F, 44 ans,
- Traitée pour Lupus
- Nivaquine: 300 mg/j, 10 ans,
- Dépistage de rétinopathie/APS
- AV: ODG: 10/10
- FO: normal ODG
- VC 15 hue: RAS



EXAMEN D'ELECTROPHYSIOLOGIE VISUELLE


ERG scototique 0.01 9mn 45s Val= 8 Rej= 0

Bi stimulé




ERG scototique 3.0 13mn 25s Val= 8 Rej= 0

Bi stimulé




ERG scototique 10 14mn 45s Val= 5 Rej= 0

Bi stimulé




OPs scototiques 3.0 17mn 58s Val= 10 Rej= 0

Bi stimulé




ERG phototique 3.0 19mn 38s Val= 21 Rej= 0

Bi stimulé




Flicker phototique 3.0 20mn 14s Val= 30 Rej= 0

Bi stimulé




OPshot 23mn 24s Val= 10 Rej= 0

Bi stimulé





ERG pattern 4mn 48s Val= 220 Rej= 15

Bi stimulé



Clinique de la Vision
Rabat
06 27 27 66 66


Moniteur
Ophtalmologique
Mon2016A



EXAMEN D'ELECTROPHYSIOLOGIE MULTIFOCALE


MERG61B
OD stimulé

CARTE DES REPONSES LOCALES
NVAQUINE 300MG J




MERG61B
OD stimulé

ANALYSE PAR ZONES (ANNEAUX)
NVAQUINE 300MG J




MERG61B
OD stimulé

CARTE AMPLITUDES ONDE P1
NVAQUINE 300MG J




MERG61B
OD stimulé

CARTE AMPLITUDES ONDE P1
NVAQUINE 300MG J




MERG61B
OG stimulé

CARTE DES REPONSES LOCALES
NVAQUINE 300MG J




MERG61B
OG stimulé

ANALYSE PAR ZONES (ANNEAUX)
NVAQUINE 300MG J




MERG61B
OG stimulé

CARTE AMPLITUDES ONDE P1
NVAQUINE 300MG J



MERG61B
OG stimulé

CARTE AMPLITUDES ONDE P1
NVAQUINE 300MG J




Rétinopathie à la chloroquine: stade pré-clinique



PRINCIPE DE L'ERG MULTIFOCAL

- Projeter sur le pôle post une matrice de petites **surfaces hexagonales, conjoint** de tailles **croissantes** (61, 103, 243...)
- Anneaux concentriques autour de **l'aire fovéale**
- ERG restreint à la surface testée, amplitudes comparables

Mosaïque de
61 hexagones



DÉROULEMENT DE L'EXAMEN




Pupilles dilatées, CO 30 cm



Électrodes cornéennes: ERG-jet (anesthésie topique)

Stimulation monoculaire



DEROULEMENT DE L'EXAMEN



STABILITÉ DE LA FIXATION



RESULTATS DE L'ERG MF



REPRÉSENTATION ET INTERPRÉTATION DES RÉSULTATS

EXAMEN D'ELECTROPHYSIOLOGIE MULTIFOCALE

MERG61B

CARTE DES REPONSES LOCALES

MERG61B


ANALYSE PAR ZONES (anneaux)

OD stimulé

BAV 03? TTT CURACNEE

OD stimulé

BAV 03? TTT CURACNEE



MERG61B

CARTE AMPLITUDES ONDE P1

MERG61B



CARTE AMPLITUDES ONDE P1

OD stimulé

BAV 03? TTT CURACNEE

OD stimulé

BAV 03? TTT CURACNEE



INDICATIONS DU MF ERG

- Maculopathies (acquises ou congénitales):

- Acquises:

- Toxicité médicamenteuse (APS +++)
 - Inflammations rétiniennes (MEWDS, AZOOR, Birdshot syndrome....)
 - DMLA, RD, CRSC, trou maculaire, MER, OVR,

- Congénitales (dystrophies)

- Stargardt (SMD), OMD, cone-rod et rod-cone dystrophies, Best...





Rétinopathie à la chloroquine et à l'hydroxychloroquine(CQ, HCQ)





- Lupus, PR, maladies inflammatoires, dermatologiques...
- Prévalence globale variable: 0,5%-7,5% (1)
- Risque très dépendant de la dose quotidienne/kg (poids réel)
- Altération des PR puis de l'EPR parafovéolaires
- 5 -10 degrés centraux (2^{ème}, 3^{ème} anneaux): maculopathie en « oeil de bœuf »
- Potentiellement irréversible, pas de TTT, progression possible après l'arrêt TTT

1. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60.

Maculopathie à l'HCQ



HCQ: 8 mg /kg X 25 ans



Marmor et al 2011 (2)

2. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquineretinopathy. *Ophthalmology* 2011;118:415–22.



American Academy of Ophthalmology Statement

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)



Michael F. Marmor, MD,¹ Ulrich Kellner, MD,² Timothy Y.Y. Lai, MD, FRCOphth,³ Ronald B. Melles, MD,⁴ William F. Mieler, MD,⁵ for the American Academy of Ophthalmology

Table 3. Clinical Examination Techniques

Not Recommended for Screening

Fundus examination

Time-domain OCT

Fluorescein angiography

Full-field ERG

Amsler grid


Color testing

EOG

EOG = electro-oculogram; ERG = electroretinogram; FAF = fundus autofluorescence; mfERG = multifocal electroretinogram; SD OCT = spectral-domain optical coherence tomography.

MERG61B
LE stimulated


MAP OF LOCAL RESPONSES




MERG61B
LE stimulated

ANALYSIS OF GROUP AVERAGES (RINGS)


AVERAGE RESPONSES (µV)



AVERAGE RMS AMPLITUDES (µV)



AVERAGE H1 P1 H2 AMPLITUDES (µV)



RING	avg(µV)	max(µV)	AVG
-2 deg	1964	3259	1.96
2-6 deg	1897	3163	0.93
6-10 deg	967	1619	0.74
10-15 deg	1110	2333	0.96
15-20 deg	1280	3373	1.86

M1 WAVE	avg(µV)	max(µV)	AVG
-2 deg	623	1027	1.43
2-6 deg	279.2	251	1.18
6-10 deg	303.3	243	3.55
10-15 deg	422.9	351	3.57
15-20 deg	433.9	247	1.00


P1 WAVE	avg(µV)	max(µV)	AVG
-2 deg	1971	4211	1.90
2-6 deg	2091	4621	2.74
6-10 deg	208	421	3.74
10-15 deg	568	435	3.91
15-20 deg	1036	474	1.00

H2 WAVE	avg(µV)	max(µV)	P1/AVG
-2 deg	1907	3571	2.50
2-6 deg	612	644	2.90
6-10 deg	729	624	2.10
10-15 deg	391	451	2.39
15-20 deg	4029	621	2.50

Rétinopathie à l'hydroxychloroquine: stade précoce


MERG61B
LE stimulated

MAP OF P1 WAVE AMPLITUDES



MERG61B
LE stimulated


MAP OF P1 WAVE AMPLITUDES



MERG62

MAP OF LOCAL RESPONSES


LE stimulated



MERG62

ANALYSIS OF GROUP AVERAGES (RINGS)

LE stimulated




Rétinopathie à l'hydroxychloroquine: satde avancé

MERG62

MAP OF P1 WAVE AMPLITUDES


LE stimulated



MERG62

MAP OF P1 WAVE AMPLITUDES


LE stimulated



AUTRES EXEMPLES D'APPLICATION DE L'ERG MULTIFOCAL


MERG61B
RE stimulated

MAP OF LOCAL RESPONSES



MERG61B
RE stimulated


ANALYSIS OF GROUP AVERAGES (RING)



Rétinopathie pigmentaire


MERG61B
RE stimulated

MAP OF P1 WAVE AMPLITUDES




MERG61B
RE stimulated

MAP OF P1 WAVE AMPLITUDES




MERG61B
RE stimulated

MAP OF LOCAL RESPONSES



MERG61B
RE stimulated


ANALYSIS OF GROUP AVERAGES (RINGS)



Maladie de Stargardt


MERG61B
RE stimulated

MAP OF P1 WAVE AMPLITUDES




MERG61B
RE stimulated

MAP OF P1 WAVE AMPLITUDES




MERG61B
LE stimulated

MAP OF LOCAL RESPONSES



MERG61B
LE stimulated


ANALYSIS OF GROUP AVERAGES (RINGS)



Choriorétinopathie de Birdshot


MERG61B
LE stimulated

MAP OF P1 WAVE AMPLITUDES



MERG61B
LE stimulated


MAP OF P1 WAVE AMPLITUDES



MULTIFOCAL ELECTROPHYSIOLOGY EXAM

MERG61B
LE stimulated

MAP OF LOCAL RESPONSES
date



MERG61B
LE stimulated


ANALYSIS OF GROUP AVERAGES (RINGS)
date



Oedème maculaire


MERG61B
LE stimulated

MAP OF P1 WAVE AMPLITUDES
date



MERG61B
LE stimulated


MAP OF P1 WAVE AMPLITUDES
date



MULTIFOCAL ELECTROPHYSIOLOGY EXAM


MERG61B
LE stimulated

MAP OF LOCAL RESPONSES
DMLA



MERG61B
LE stimulated


ANALYSIS OF GROUP AVERAGES (RINGS)
DMLA



DMLA


MERG61B
LE stimulated

MAP OF P1 WAVE AMPLITUDES
DMLA



MERG61B
LE stimulated

MAP OF P1 WAVE AMPLITUDES
DMLA



TAKE HOME MESSAGES



- L'ERG flash peut occulter des déficits de fonctionnement **localisés** et **non systématisés** de la rétine centrale
- L'ERG multifocal détecte ces déficits et les localise
- Appoint important à l'imagerie multimodale moderne
- Doit **toujours** être interprété associé aux renseignements cliniques et aux résultats **des autres explorations**